2
Dec
2021

The Variant on the Move

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

AbbVie Acquires Apogee, FDA Changes Tune on RegenxBio, & Merck Seizes TL1A Lead
Kardigan Continues IPO Trend & FDA Reconsiders UniQure and Moderna
Parabilis IPO Pops, J&J Buys More Degraders, & GSK’s Precision Oncology Bet
RevMed’s Moment in the Sun, In Vivo CAR-Ts Shine & NewLimit’s Healthspan Haul